A Birthday for the Wild Scientist in the Room

Psychedelics

Jun 17

The Dose of Wonder: Celebrating Sasha Shulgin’s 101st Birthday and the Chemistry of Human Curiosity

This month, the psychedelic research community is celebrating what would have been Alexander “Sasha” Shulgin’s 101st birthday. The reference image centers on a Shulgin Foundation post inviting people to share memories, gratitude, and love for Sasha and Ann Shulgin — two names that sit at the strange crossroads of chemistry, therapy, spirituality, controversy, and cultural transformation.

Sasha Shulgin was born on June 17, 1925, and died on June 2, 2014. Purdue University’s archives note that he earned his Ph.D. in biochemistry from UC Berkeley in 1954 and later worked as a senior research chemist at Dow Chemical before becoming deeply involved in psychoactive chemistry.

But calling Shulgin “just a chemist” is like calling lightning “slightly energetic weather.” He became one of the most influential and controversial figures in psychedelic science, not because he gave clean TED Talk answers, but because he asked dangerous, beautiful, complicated questions:

What can chemistry reveal about consciousness?
Can molecules help humans heal?
Where is the line between discovery and recklessness?
And who gets to decide what forms of inner exploration are legal, medical, sacred, or forbidden?

That last question is where the story gets spicy — because apparently humanity can split the atom, build AI, and sell energy drinks named like war crimes, but still panic when someone says, “Maybe the mind deserves careful exploration.”

Sasha Shulgin Was Not the “Inventor of MDMA” — Let’s Get That Straight

One of the biggest myths around Sasha Shulgin is that he “invented MDMA.” He did not.

The compound was first synthesized decades earlier, but Shulgin played a major role in bringing MDMA into modern psychopharmacology and therapeutic circles. A historical review in Addiction concluded that Shulgin was not the first to synthesize MDMA, but he was central to its later history because he introduced it to therapist Leo Zeff in 1977 and co-published an early human pharmacology report with David Nichols in 1978.

That distinction matters. History deserves a microscope, not a fog machine.

Shulgin’s real contribution was not simply “making molecules.” His deeper impact was building a bridge between chemistry, subjective experience, documentation, and therapeutic possibility. He treated altered states as data — messy data, human data, deeply subjective data, but data nonetheless.

That approach made him a legend to some, a problem to others, and a headache to anyone who prefers human consciousness to stay neatly boxed like cereal on a government shelf.

The Shulgin Farm: A Tiny Lab With a Massive Shadow

The Shulgin Foundation describes itself as a 501(c)(3) nonprofit dedicated to conserving the legacy and work of Ann and Sasha Shulgin through science, therapeutic insight, spiritual inquiry, and community.

At the heart of that legacy is Shulgin Farm in Lafayette, California. The Foundation describes the farm’s small laboratory as a 200-square-foot space where Sasha carried out years of chemical research, and credits him with creating more than 150 novel psychedelic compounds.

Think about that for a second.

Not a skyscraper.
Not a billion-dollar campus.
Not a glossy biotech fortress with glass walls and espresso machines named “innovation hubs.”

A small lab. A notebook. A disciplined mind. A willingness to explore.

That is both inspiring and terrifying. Because the Shulgin story reminds us that discovery does not always arrive wearing institutional badges. Sometimes it arrives in a shed, holding a beaker, asking questions polite society is not ready to answer.

Ann Shulgin: The Other Half of the Chemical Love Story

Any serious tribute to Sasha that does not honor Ann Shulgin is only telling half the story.

Sasha brought the chemistry. Ann brought psychological, spiritual, and therapeutic depth. Together, they wrote PiHKAL: A Chemical Love Story and TiHKAL: The Continuation, works that became foundational texts in psychedelic culture and controversial landmarks in drug literature. Purdue’s archive describes PiHKAL as both an autobiographical story and a chronicle of the authors’ work involving phenethylamines.

Their partnership mattered because the psychedelic question was never only chemical.

It was emotional.
Relational.
Therapeutic.
Existential.
Human.

Ann’s work helped frame psychedelics not as fireworks for the bored, but as potentially meaningful tools when handled with preparation, respect, boundaries, and care.

In plain English: the molecule is not the medicine by itself. The container matters. The therapist matters. The intention matters. The integration matters. The ethics matter. The human being matters.

Without that, “consciousness exploration” becomes just another guy in a wolf hoodie explaining enlightenment after ruining Thanksgiving.

The 2026 Context: Psychedelic Science Is Growing Up

Sasha’s 101st birthday arrives at a strange and important time.

Psychedelic research has moved from counterculture whispers into universities, clinical trials, veteran mental health programs, biotech investment, and government debate. But the field is not floating on a rainbow cloud of guaranteed approval.

MDMA-assisted therapy for PTSD is still a major example of both promise and friction. MAPS states that MDMA-assisted therapy remains under investigation and is not yet approved by the FDA, while noting that FDA had previously designated it a Breakthrough Therapy.

A 2023 Phase 3 study published in Nature Medicine reported that MDMA-assisted therapy reduced PTSD symptoms and functional impairment in a diverse group with moderate to severe PTSD, while also documenting severe treatment-emergent adverse events in some participants.

Then came the regulatory wall. The FDA declined to approve Lykos Therapeutics’ MDMA-assisted therapy application in 2024 and requested additional Phase 3 research; later reporting and FDA-related documentation pointed to concerns involving trial design, durability, conduct, and data integrity.

That does not mean the field is dead. It means the field is being forced to mature.

And honestly? Good.

Because if psychedelic medicine wants to enter hospitals, veterans’ clinics, trauma centers, and mainstream mental health systems, it cannot operate like a festival campsite with a clipboard. It needs rigorous trials, ethical safeguards, adverse event reporting, trained facilitators, clear boundaries, and boring paperwork — the kind of paperwork that makes your soul yawn but keeps people alive.

The Real Legacy: Curiosity With Consequences

The most important lesson from Sasha Shulgin is not “psychedelics are good” or “psychedelics are bad.”

That binary is lazy. It belongs in the same intellectual dumpster as “technology will save us” and “technology will destroy us.”

The real lesson is this:

Powerful tools require powerful ethics.

Chemistry can heal or harm.
AI can liberate or manipulate.
Medicine can serve people or become an industry treadmill.
Spirituality can awaken people or become a costume party for narcissists.

Shulgin’s legacy forces us to wrestle with complexity. He was not a cartoon hero. He was not a cartoon villain. He was a brilliant, controversial scientist whose work opened doors that society is still arguing about how to walk through.

That is why the Shulgin Foundation’s birthday invitation matters. It is not just nostalgia. It is a cultural checkpoint.

A birthday asks: What are we carrying forward?

Are we carrying forward curiosity? Good.
Are we carrying forward careful documentation? Excellent.
Are we carrying forward reverence for Ann’s therapeutic wisdom? Necessary.
Are we carrying forward reckless DIY chemistry, illegal sourcing, or amateur “healing” theater? Absolutely not. Throw that in the volcano.

The Ethical Line: No Recipes, No Cowboy Chemistry, No Fake Shamans

Let’s be blunt.

This article does not provide chemical synthesis instructions, dosage guidance, sourcing advice, or encouragement to use illegal substances. Psychedelic compounds can carry psychological, cardiovascular, legal, and social risks, especially outside clinical settings or for people with certain mental health histories.

Respecting Sasha’s legacy does not mean copying his methods in your garage like a discount wizard with poor ventilation.

The modern field needs:

1. Clinical research over hype

Promising data is not the same as approval. Early breakthroughs still need replication, oversight, safety monitoring, and long-term follow-up.

2. Trained care over influencer therapy

A person with a ring light and a mushroom necklace is not automatically a therapist. Shocking, I know.

3. Integration over intoxication

The “experience” is not the whole story. What happens afterward — reflection, behavior change, therapy, community support — may matter just as much.

4. Consent over charisma

No healer, therapist, guide, or facilitator should ever hide behind mystical language to avoid professional boundaries.

5. Access without exploitation

If psychedelic medicine becomes legal only for the wealthy, then we did not build healing. We built a luxury spa wearing a lab coat.

Why Men 25–45 Should Care

For men across America, Germany, Canada, Mexico, Brazil, and beyond, the Shulgin conversation hits deeper than drug history.

A lot of men are quietly carrying trauma, depression, grief, addiction patterns, emotional shutdown, burnout, and loneliness. Many were trained to “man up,” which is often just society’s poetic way of saying, “Please emotionally rot in silence so nobody feels uncomfortable.”

Psychedelic research is part of a larger cultural question:

How do we help people heal when the old tools are not enough?

That does not mean every man needs psychedelics. It means we need more honest conversations about mental health, consciousness, therapy, connection, and meaning.

Sasha and Ann’s work matters because it challenged the idea that the mind is only a machine to be medicated into obedience. They helped reopen the possibility that healing may involve memory, emotion, love, body, ritual, chemistry, relationship, and integration.

Not magic.
Not escapism.
Not “bro, the universe told me to start a podcast.”

Actual healing.

The Birthday Message: Thank You, Sasha and Ann

So today’s Blogger Paper is a thank-you note with a safety label.

Thank you, Sasha, for showing that curiosity can be radical.
Thank you, Ann, for reminding the field that chemistry without humanity is incomplete.
Thank you to the archivists, researchers, therapists, scientists, and ethical practitioners preserving the Shulgin legacy without turning it into reckless mythology.
And thank you to everyone trying to build a psychedelic future that is not just profitable, but responsible.

Because that is the real birthday candle we should be lighting:

Not worship. Not hype. Not rebellion for rebellion’s sake.

A commitment.

To science.
To healing.
To honesty.
To human dignity.
To curiosity with guardrails.
To wonder without delusion.
To love without exploitation.

Sasha Shulgin’s 101st birthday is not just a date on the psychedelic calendar. It is a reminder that the future of consciousness research must be brave enough to explore and mature enough to be accountable.

That is the difference between a movement and a mess.

And let’s be honest — humanity already has enough messes. We are fully stocked. 🧪🔥

What chemistry can reveal about consciousness

Chemistry can reveal at least three things about consciousness with unusual precision: which molecular targets shift conscious state, which neuromodulators bias perception and emotion, and which large-scale network reconfigurations accompany those shifts. In classic psychedelics, the strongest mechanistic signal is serotonin 5-HT2A receptor agonism. In humans, ketanserin blocks or sharply attenuates the subjective and neural effects of LSD and psilocybin, which is why 5-HT2A has become the leading receptor-level handle on classic psychedelic consciousness research. At the same time, receptor action is not identical to the whole experience: contemporary reviews emphasize that psychedelics engage multiple targets and downstream pathways, so the same subjective state cannot be reduced to one receptor alone.

At the network level, the clearest current picture is that classic psychedelics reduce segregation within canonical brain networks and increase communication across them. Psilocybin has been shown to massively disrupt functional connectivity in cortex and subcortex — more than threefold greater than methylphenidate in one precision-mapping study — with some changes detectable for weeks. LSD alters effective connectivity in cortico-striato-thalamo-cortical pathways, and broader meta-analytic work suggests psychedelics generally decrease within-network connectivity while increasing between-network connectivity. These findings fit models such as REBUS, which propose that psychedelics relax high-level priors and amplify bottom-up signaling, thereby changing the balance between expectation and sensation.

MDMA and other entactogens reveal a different side of consciousness. Rather than being primarily “visionary,” MDMA acts principally as a serotonin, norepinephrine, and dopamine reuptake inhibitor/releasing agent, with especially strong serotonergic action and downstream effects that appear relevant to oxytocin, affiliative processing, and social reward. Human studies and recent reviews suggest MDMA enhances emotional openness, positive responses to social feedback, and empathic resonance. Neuroimaging work also indicates that acute MDMA can reduce connectivity between limbic striatum and amygdala, which is consistent with the long-standing hypothesis that it may create a temporary window in which fear is less dominant and trauma processing becomes more tolerable.

A broader lesson follows from modern “network pharmacology” work: conscious effects are best understood as many-to-many mappings among receptor systems, brain topology, and subjective reports. Analyses linking thousands of psychoactive experience reports to receptor-binding profiles, and brain-imaging studies mapping pharmacologically induced changes onto neurotransmitter architectures, both argue against simplistic one-molecule/one-experience stories. Chemistry gives us causal levers; it does not yield a complete ontology of mind.

That is the limit of chemical explanation. Psychedelics are especially informative for what philosophers call the “easy problems” of consciousness — relations among subjectivity, behavior, neural signaling, and reportability — but they do not settle the “hard problem” of why any of these processes are accompanied by felt experience. Even within neuroscience, current consciousness work treats conscious states as dynamic patterns of coordinated brain signaling rather than as something exhausted by neurotransmitter concentrations alone. The strongest scientifically defensible position is therefore modest: chemistry can expose the control knobs of conscious state changes, but it does not yet explain consciousness as such.

Can molecules help humans heal

For PTSD, MDMA has the most advanced evidence base among non-approved psychedelics. In the first Phase 3 trial, MDMA-assisted therapy significantly reduced CAPS-5 PTSD severity relative to placebo with therapy, with a between-group effect size of d = 0.91 and 67% of completers no longer meeting diagnostic criteria for PTSD at the primary endpoint, versus 32% in the placebo-with-therapy arm. In the second Phase 3 trial, the between-group effect size was d = 0.70, with 71.2% no longer meeting DSM-5 PTSD criteria in the MDMA-assisted group versus 47.6% in placebo with therapy. These are clinically meaningful signals in adults with long-standing PTSD, but they were generated in highly structured, therapist-intensive protocols and in populations that excluded some of the highest-risk patients, including those with major cardiovascular disease and high suicide risk.

For depression, psilocybin’s evidence is promising but more heterogeneous. In the 2022 Phase 2b NEJM trial in treatment-resistant depression, a single 25 mg dose reduced depression scores significantly more than 1 mg over three weeks, but the advantage was not clearly sustained at 12 weeks; adverse events were common, and suicidal ideation/behavior or self-injury occurred across dose groups, including serious events in the 25 mg arm. In a small randomized clinical trial in major depressive disorder, psilocybin-assisted therapy produced large, rapid, and sustained symptom improvement over one month. Longer-term and head-to-head data remain contested: a 2021 psilocybin-versus-escitalopram trial did not show a significant difference on its primary endpoint at six weeks, though several secondary outcomes favored psilocybin. A 2025 meta-analysis of randomized psilocybin trials in MDD concluded that antidepressant effects were superior to comparators with at least medium effect sizes, but a 2026 JAMA Psychiatry meta-analysis argued that under “equal unblinding” assumptions psychedelic therapy was not more effective than open-label antidepressants, highlighting how much expectancy and masking still matter in interpretation.

For anxiety disorders, LSD has credible but still smaller-scale evidence. A modern randomized trial reported long-lasting benefits of LSD-assisted therapy in patients with anxiety, with one treatment-related serious adverse event of acute transient anxiety and transient negative effects in about 19% of participants. Phase 3 programs for LSD-derived MM120 in generalized anxiety disorder are now listed on ClinicalTrials.gov, which means the evidence base is moving forward, but LSD remains much less mature clinically than MDMA for PTSD or psilocybin for depression.

The therapy model matters. Most modern psychedelic trials are not simple drug-alone studies; they pair the medicine with preparation, supervised dosing, and integration. FDA reviewers explicitly criticized the MDMA application because psychotherapy’s contribution was not disentangled and suggested factorial designs to separate drug and therapy effects. A 2026 meta-analysis found that more preparatory therapy was associated with greater depressive symptom reduction in psychedelic-assisted therapy, while a complementary 2026 review concluded that the “psychological support” used in most trials qualifies as psychotherapy in practice. In other words, current evidence generally supports treatment packages, not molecule-only claims.

Safety is real, not incidental. Across controlled psychedelic and MDMA treatments, the most common acute or subacute adverse effects include headache, nausea, dizziness, temporary anxiety, fatigue, low mood, elevated blood pressure, and emotionally challenging experiences; serious adverse events are uncommon in screened, supervised settings but do occur. Broader evidence syntheses describe low rates of emergent serious adverse events under controlled conditions, while also warning that adverse-event reporting has often been inconsistent and underdefined. Recent JAMA Psychiatry reporting has also sharpened a separate point: some of the most serious risks in psychedelic-assisted therapy come from the therapeutic relationship itself, not only from the drug.

Most studied populations have been relatively narrow. Modern trials usually enroll adults, often with chronic or treatment-resistant illness, but commonly exclude people with psychotic disorders, bipolar disorder, major cardiovascular instability, or high near-term suicide risk. That improves internal safety, but it also limits generalizability. The strongest answer to “can molecules help humans heal?” is therefore conditional: yes, in some disorders, for some screened populations, in structured settings, with trained support, and not yet with the certainty that public rhetoric often implies.

Where discovery becomes recklessness

The best ethical frameworks still start with basics. The Belmont Report formalized respect for persons, beneficence, and justice; the Declaration of Helsinki grounds modern human-subjects research in participant welfare and informed consent; and ICH E6(R3) Good Clinical Practice emphasizes quality by design, proportional oversight, credible data, and protection of participants. For psychedelic research, those are not abstract ideals. They are direct answers to the field’s recurring temptations: charismatic overreach, weak masking, inflated claims, underreported harms, and the confusion of “transformative” with “safe.”

Shulgin is the clearest historical case study in both directions. His small Lafayette lab helped generate an enormous amount of exploratory knowledge, and the Shulgin Foundation still describes the Farm as the place where Sasha created more than 150 compounds and where he and trusted collaborators logged trip reports over thousands of sessions. But the same Foundation also documents a culture of self-experimentation and close-circle testing that would not satisfy modern standards for independent oversight, adverse-event reporting, representative sampling, or protection against coercion and bias. Shulgin’s legacy is thus best read as proof of conceptual discovery, not proof of evidentiary sufficiency.

The modern field has already shown what happens when rigor is not strong enough. FDA reviewers argued in 2024 that functional unblinding and expectation bias likely affected the interpretability of MDMA trial results, that durability data were difficult to interpret, and that the role of psychotherapy remained unresolved. The FDA’s complete response letter then concluded that these limitations, along with failures to establish durable effect convincingly, precluded a finding of substantial evidence of effectiveness and pointed toward the need for another trial. Separately, retraction notices for several MDMA-assisted psychotherapy papers cited protocol violations amounting to unethical conduct at a study site. Those episodes do not prove the treatment is ineffective; they show that therapeutic promise does not excuse weak safeguards or poor reporting.

Psychedelic-assisted therapy adds a distinctive ethical hazard: the participant is often unusually suggestible, emotionally open, and dependent on the immediate therapeutic container. Commentaries and reviews now explicitly warn that patient vulnerability and abuses of power may be among the field’s most serious risks. That is why trained, licensed therapists; clear boundaries; emergency procedures; supervision; complaint pathways; and strong documentation are not mere administrative details — they are part of the treatment itself. Health Canada’s guidance is notable here: it expects evidence-informed protocols, therapist qualifications, and direct supervision of unlicensed team members in psychedelic clinical trials.

DIY chemistry is where discovery most obviously becomes recklessness. Authoritative safety guidance from ACS and OSHA emphasizes that flammable solvents, incompatible chemicals, oxidizers, compressed gases, high-pressure glassware, and reduced/elevated-pressure operations all create real risks of fire, explosion, eye injury, toxic exposure, and skin absorption. NIOSH has likewise documented that clandestine drug labs can release toxic gases, create hazardous waste, and expose workers and first responders to significant chemical danger. That means the risk is not only legal or moral; it is practical, immediate, and sometimes catastrophic.

The line, analytically, is this: discovery becomes recklessness when the expected epistemic or therapeutic gain no longer clearly justifies the participant, operator, or bystander risk — or when the design lacks the safeguards needed to know what happened. Under that standard, careful clinical investigation can be ethical even for controversial compounds; self-authorizing experimentation, informal underground practice without robust protections, and unsupervised chemistry usually cannot.

Who decides legality, medical use, and sacred status

No single actor decides all statuses at once. Legality is shaped by drug-control law and treaty architecture; medical status is decided through evidence and regulatory review; sacred status is grounded in community, tradition, and protected practice. In the United States, DEA scheduling still places MDMA, LSD, psilocybin, mescaline, and peyote in Schedule I federally, while the 1971 UN Convention on Psychotropic Substances provides a broad international control framework for LSD, psilocybin, and related substances. But Schedule I status does not prevent research automatically; the DEA has explicitly maintained research pathways for Schedule I studies, and the FDA has issued drug-development guidance specific to psychedelic clinical investigations.

Medical status is decided by regulators asking a narrower question than culture usually asks: is there adequate evidence of effectiveness and acceptable evidence of safety for a defined indication, in a defined population, under a defined treatment model? In the FDA system, that means IND development, trial design, CMC quality, safety monitoring, and finally a benefit-risk decision on marketing authorization. The midomafetamine case is the current object lesson: Breakthrough Therapy designation helped development, but it did not guarantee approval, and the FDA ultimately rejected the application for PTSD. In Europe, EMA’s 2024 multi-stakeholder workshop made clear that psychedelics will be regulated under general drug-approval standards, with special attention to expectancy bias, blinding, standardization of setting and training, psychotherapy’s role, maintenance of effect, addiction potential, and risk minimization measures.

National and subnational governments then build very different access models on top of that baseline. Australia’s TGA moved MDMA and psilocybin into controlled access for tightly defined indications through authorized psychiatrists beginning in 2023. Canada has used the Special Access Program for case-by-case access and set expectations for therapist qualifications in clinical trials. Oregon created licensed psilocybin services as a regulated health-and-wellness model rather than an FDA-style medical approval, while Colorado created a broader natural-medicine regulatory system that includes facilitator licensing and a formal Federally Recognized American Tribes and Indigenous Community Working Group. The Czech Republic’s 2025 reform, effective from January 2026, created a lawful therapeutic psilocybin route under national law. These are not just different rules; they reflect different theories of what psychedelic legitimacy is supposed to mean.

Sacred status is different again. The U.S. legal system has long recognized accommodation questions around peyote and the Native American Church, while the UN Declaration on the Rights of Indigenous Peoples affirms Indigenous peoples’ rights to traditional medicines and health practices. Colorado’s regulatory design is particularly instructive because it formally embeds Indigenous-traditional-use representation and a tribes/Indigenous working group into governance. The implication is important: regulators can accommodate sacred use, constrain it, or ignore it, but they do not create sacred legitimacy out of nothing. Sacred authority is claimed and maintained by communities, lineages, and protected practices, not granted by a drug label.

The deepest policy tension is therefore plural. Researchers want cleaner evidence; industry wants approvable products; therapists want workable models; patients want access; Indigenous communities want respect, reciprocity, and protection from extraction; regulators want a positive benefit-risk balance; advocacy groups want reform; and payers want scalable, reimbursable care. EMA’s workshop format — explicitly bringing together patients, healthcare professionals, academia, regulators, and industry — is a good snapshot of the real governance map. The unresolved question is not who gets the only voice. It is how those voices are weighted when evidence, commerce, culture, and spirituality point in different directions.

A pattern emerges from comparison: the more “transformative” the acute subjective effect, the harder trial masking, therapist standardization, and expectation control become. That is why efficacy debates in psychedelics now increasingly turn on design quality as much as on signal magnitude.

  
    Timeline
    Title From Shulgin to the current psychedelic policy landscape
: Alexander T. Shulgin born
: Shulgin and Nichols publish early human psychotomimetic characterization work including MDMA-era compounds
: DEA temporarily places MDMA in Schedule I
: MDMA Schedule I status confirmed after hearings and appeals
: PiHKAL published
: TiHKAL published
: Sasha Shulgin dies
: First modern MDMA Phase 3 PTSD trial reports positive results
: Second MDMA Phase 3 PTSD trial positive
: Australia opens tightly controlled MDMA and psilocybin prescribing pathway
: FDA advisory review highlights unblinding, durability, and psychotherapy-design problems
: FDA issues complete response letter declining MDMA approval for PTSD
: Shulgin Foundation marks Sasha's 101st birthday amid ongoing psychedelic regulatory realignment
  

The historical arc is striking. Shulgin’s life work helped create the chemical vocabulary; federal scheduling shut much of that world down; books like PiHKAL and TiHKAL preserved and disseminated the exploratory archive; modern Phase 3 trials reopened the medical question; and current regulators are now trying to decide whether the field can mature from subculture and charisma into reproducible medicine.